Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innovent Biologics, Inc.

http://www.innoventbio.com/en/

Latest From Innovent Biologics, Inc.

China’s Public Payer Challenged To Support Domestic Innovative Drug Market

One Chinese biotech executive is entertaining hopes of China’s domestic market for novel drugs growing to CNY300bn ($41bn). However, the country’s public payer spent just CNY90bn on such products in 2023 and is expected to increase expenditure to more than CNY100bn this year.

China Reimbursement

Will US Clinical Study Diversity Guidance Cloud Chinese Firms’ Prospects For Going Global?

The latest FDA guidance will have profound impact to Chinese biotech sector at a time when going global and a US approval is vital to its very survival.

Diversity & Inclusion Clinical Trials

ADA: Hengrui, Innovent’s Incretins Shine In China Obesity Studies

Positive clinical outcomes for Hengrui and Innovent/Lilly’s obesity candidates presented at ADA were based on trials that enrolled Chinese subjects and were characterized by fewer women and less severe obesity than similar Western studies. Even so, some of the data appear to stack up well against western rival drugs.

China Metabolic Disorders

China Biotech Podcast: 数据出境新规解读,EHA和ADA的中国数据发布

In this Chinese-language podcast episode, "Angus" Shipo Xie, a lawyer at Han Kun Law, joins Brian Yang to discuss the implications of China's updated Data Overseas Transfer rules issued in late March. Dexter Yan explains clinical data released by Hutchmed, Jiangsu Hengrui and Innovent Bio at the recent EHA and ADA annual conferences.

China Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Innovent Biologics (Suzhou) Co., Ltd.
UsernamePublicRestriction

Register